Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2019

05.12.2018 | Original Article

Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012–2017

verfasst von: Mohannad Abou Saleh, Emad Mansoor, Mohammad Anindo, Gerard Isenberg

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

Most carcinoid tumors of the gastrointestinal tract are located in the small bowel (SB). Epidemiological studies of these tumors have been limited by small sample sizes. Our aim was to evaluate the epidemiology of SB carcinoids (SBCs) using a large database.

Methods

We queried a commercial database (Explorys), an aggregate of electronic health data from 26 US healthcare systems. We identified patients with SBCs between 2012 and 2017. We evaluated the epidemiology of SBC and identified possible risk factors.

Results

Of the 35,798,290 individuals in the database between 2012 and 2017, we identified 3280 patients with SBCs, with a prevalence of 9.2/100,000. Prevalence was higher in men [odds ratio (OR) 1.23, 95% confidence interval (CI) 1.153–1.322, p < 0.0001], whites [OR 2.031, 95% CI 1.872–2.203, p < 0.0001], and elderly (aged > 65) [OR 4.856, 95% CI 4.533–5.203, p < 0.0001]. Patients with SBCs were more likely to have a history of smoking [OR 2.749, 95% CI 2.549–2.970, p < 0.0001], alcohol use [OR 2.031, 95% CI 1.864–2.21, p < 0.0001], obesity (BMI > 30) [OR 3.476, 95% CI 3.213–3.761, p < 0.0001], diabetes mellitus [OR 4.198, 95% CI 3.900–4.519, p < 0.0001], and a family history of cancer [OR 5.902, 95% CI 5.396–6.456, p < 0.0001].

Conclusions

This is one of the largest studies done on the prevalence of SBC. The prevalence of 9.2/100,000 individuals is higher than previously reported. Further genetic and environmental studies are needed to understand the potential mechanisms for the risk factors identified in this study.
Literatur
1.
Zurück zum Zitat Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.CrossRefPubMed Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.CrossRefPubMed
2.
Zurück zum Zitat Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–712.CrossRefPubMed Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–712.CrossRefPubMed
3.
Zurück zum Zitat KlÖppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.CrossRefPubMed KlÖppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.CrossRefPubMed
4.
Zurück zum Zitat Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. The Lancet. 1998;352:799–805.CrossRef Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. The Lancet. 1998;352:799–805.CrossRef
6.
Zurück zum Zitat von der Ohe MR, Michael C, Larry KK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329:1073–1078.CrossRefPubMed von der Ohe MR, Michael C, Larry KK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329:1073–1078.CrossRefPubMed
8.
Zurück zum Zitat Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–1196.CrossRefPubMed Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–1196.CrossRefPubMed
9.
Zurück zum Zitat Yao JC, Hassan M, Phan A, Dagohoy C, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.CrossRefPubMed Yao JC, Hassan M, Phan A, Dagohoy C, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.CrossRefPubMed
10.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.CrossRefPubMed Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.CrossRefPubMed
11.
Zurück zum Zitat Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813–829.CrossRefPubMed Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813–829.CrossRefPubMed
12.
13.
Zurück zum Zitat Barclay THC, Schapira DV. Malignant tumors of the small intestine. Cancer. 1983;51:878–881.CrossRefPubMed Barclay THC, Schapira DV. Malignant tumors of the small intestine. Cancer. 1983;51:878–881.CrossRefPubMed
14.
Zurück zum Zitat Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors. Cancer. 2001;92:2204–2210.CrossRefPubMed Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors. Cancer. 2001;92:2204–2210.CrossRefPubMed
15.
Zurück zum Zitat Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987;206:115.CrossRefPubMedPubMedCentral Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987;206:115.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295–1300.CrossRefPubMed Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295–1300.CrossRefPubMed
17.
Zurück zum Zitat Uhr JH, Shah J, Warner RR, et al. Racial disparities in clinical presentation and surgical outcomes in patients with small bowel carcinoid tumors. Am Surg. 2016;82:E89.PubMed Uhr JH, Shah J, Warner RR, et al. Racial disparities in clinical presentation and surgical outcomes in patients with small bowel carcinoid tumors. Am Surg. 2016;82:E89.PubMed
18.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.CrossRefPubMed Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.CrossRefPubMed
19.
Zurück zum Zitat Kaerlev L, Teglbjaerg PS, Sabroe S, et al. The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case–control Study. Cancer Causes Control. 2002;13:27–34.CrossRefPubMed Kaerlev L, Teglbjaerg PS, Sabroe S, et al. The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case–control Study. Cancer Causes Control. 2002;13:27–34.CrossRefPubMed
20.
Zurück zum Zitat Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry. Arch Surg. 2007;142:229–235.CrossRefPubMed Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry. Arch Surg. 2007;142:229–235.CrossRefPubMed
21.
Zurück zum Zitat Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80:3–7.CrossRefPubMed Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80:3–7.CrossRefPubMed
22.
Zurück zum Zitat Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control. 2005;16:781–787.CrossRefPubMed Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control. 2005;16:781–787.CrossRefPubMed
23.
Zurück zum Zitat Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Prev Biomark. 1998;7:243–251. Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Prev Biomark. 1998;7:243–251.
24.
Zurück zum Zitat Seydafkan S, Coppola D. Neuroendocrine neoplasms of the small intestine. In: Nasir A, Coppola D, eds. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. New York: Springer; 2016:273–288.CrossRef Seydafkan S, Coppola D. Neuroendocrine neoplasms of the small intestine. In: Nasir A, Coppola D, eds. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. New York: Springer; 2016:273–288.CrossRef
25.
Zurück zum Zitat Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24:3040–3044.CrossRefPubMed Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24:3040–3044.CrossRefPubMed
27.
Zurück zum Zitat Naef M, Bühlmann M, Baer HU. Small bowel tumors: diagnosis, therapy and prognostic factors. Langenbeck’s Arch Surg. 1999;384:176–180.CrossRef Naef M, Bühlmann M, Baer HU. Small bowel tumors: diagnosis, therapy and prognostic factors. Langenbeck’s Arch Surg. 1999;384:176–180.CrossRef
28.
Zurück zum Zitat Chow WH, Linet MS, McLaughlin JK, et al. Risk factors for small intestine cancer. Cancer Causes Control. 1993;4:163–169.CrossRefPubMed Chow WH, Linet MS, McLaughlin JK, et al. Risk factors for small intestine cancer. Cancer Causes Control. 1993;4:163–169.CrossRefPubMed
29.
Zurück zum Zitat Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer. 1997;70:512–517.CrossRefPubMed Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer. 1997;70:512–517.CrossRefPubMed
30.
Zurück zum Zitat Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2015;27:68–81.CrossRefPubMed Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2015;27:68–81.CrossRefPubMed
31.
Zurück zum Zitat Cross AJ, Leitzmann MF, Subar AF, et al. Prospective study of meat and fat intake in relation to small intestinal cancer. Can Res. 2008;68:9274–9279.CrossRef Cross AJ, Leitzmann MF, Subar AF, et al. Prospective study of meat and fat intake in relation to small intestinal cancer. Can Res. 2008;68:9274–9279.CrossRef
33.
35.
Zurück zum Zitat Scosyrev E, Messing J, Noyes K, Veazie P, et al. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012;30:126–132.CrossRefPubMed Scosyrev E, Messing J, Noyes K, Veazie P, et al. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012;30:126–132.CrossRefPubMed
36.
Zurück zum Zitat Makridis C, Öberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–383.CrossRefPubMed Makridis C, Öberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–383.CrossRefPubMed
37.
Zurück zum Zitat Kulke MH, Freed E, Chiang DY, et al. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosom Cancer. 2008;47:591–603.CrossRefPubMed Kulke MH, Freed E, Chiang DY, et al. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosom Cancer. 2008;47:591–603.CrossRefPubMed
38.
Zurück zum Zitat Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a US-based case–control study. Int J Cancer. 2008;123:867–873.CrossRefPubMed Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a US-based case–control study. Int J Cancer. 2008;123:867–873.CrossRefPubMed
39.
Zurück zum Zitat Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia Type 1. Medicine. 1997;76:21–29.CrossRefPubMed Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia Type 1. Medicine. 1997;76:21–29.CrossRefPubMed
40.
Zurück zum Zitat Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg. 2009;33:1197–1207.CrossRefPubMed Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg. 2009;33:1197–1207.CrossRefPubMed
41.
Zurück zum Zitat Berna MJ, Annibale B, Marignani M, et al. Prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia Type 1 and Zollinger–Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93:1582–1591.CrossRefPubMedPubMedCentral Berna MJ, Annibale B, Marignani M, et al. Prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia Type 1 and Zollinger–Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93:1582–1591.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Babovic-Vuksanovic D, Constantinou CL, Rubin J, et al. Familial occurrence of carcinoid tumors and association with other malignant neoplasms. Cancer Epidemiol Prev Biomark. 1999;8:715–719. Babovic-Vuksanovic D, Constantinou CL, Rubin J, et al. Familial occurrence of carcinoid tumors and association with other malignant neoplasms. Cancer Epidemiol Prev Biomark. 1999;8:715–719.
43.
Zurück zum Zitat West NE, Wise PE, Herline AJ, et al. Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13:1129–1134.CrossRefPubMed West NE, Wise PE, Herline AJ, et al. Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13:1129–1134.CrossRefPubMed
44.
Zurück zum Zitat Kaerlev L, Teglbjaerg PS, Sabroe S, et al. Occupational risk factors for small bowel carcinoid tumor: a European population-based case–control study. J Occup Environ Med. 2002;44:516–522.CrossRefPubMed Kaerlev L, Teglbjaerg PS, Sabroe S, et al. Occupational risk factors for small bowel carcinoid tumor: a European population-based case–control study. J Occup Environ Med. 2002;44:516–522.CrossRefPubMed
46.
Zurück zum Zitat Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol. 2017;15:1733–1741.CrossRefPubMed Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol. 2017;15:1733–1741.CrossRefPubMed
47.
Zurück zum Zitat Kaelber DC, Foster W, Gilder J, et al. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc. 2012;19:965–972.CrossRefPubMedPubMedCentral Kaelber DC, Foster W, Gilder J, et al. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc. 2012;19:965–972.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016;91:81–83.CrossRefPubMed Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016;91:81–83.CrossRefPubMed
Metadaten
Titel
Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012–2017
verfasst von
Mohannad Abou Saleh
Emad Mansoor
Mohammad Anindo
Gerard Isenberg
Publikationsdatum
05.12.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5402-z

Weitere Artikel der Ausgabe 5/2019

Digestive Diseases and Sciences 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.